InsiderTrades

Form 4 for MGNX MACROGENICS INC

Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-12 · accession 0001587774-26-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-02-17 2026-02-15 MGNX Risser Eric Blasius Pres, CEO, Dir M - OptEx — +16.7K 83.6K +25% —
D 2026-02-17 2026-02-15 MGNX Risser Eric Blasius Pres, CEO, Dir F - Tax $1.71 -6,433 77.2K -8% -$11.0K
D 2026-02-17 2026-02-15 MGNX Risser Eric Blasius Pres, CEO, Dir M - OptEx $0.00 -16.7K 0 -100% $0
DM 2026-02-17 2026-02-12 MGNX Risser Eric Blasius Pres, CEO, Dir A - Grant $0.00 +695.0K 595.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-15 M A 16,665 — 83,602 D — — (F1) On February 15, 2023, the reporting person was granted 50,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.
2 Common Common Stock 2026-02-15 F D 6,433 $1.71 77,169 D — —
3 Derivative Restricted Stock Unit 2026-02-15 M D 16,665 $0.00 0 D — · — to — 16,665 Common Stock (F1) On February 15, 2023, the reporting person was granted 50,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.
4 Derivative Restricted Stock Unit 2026-02-12 A A 100,000 $0.00 100,000 D — · — to — 100,000 Common Stock (F2) Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.
5 Derivative Employee Stock Option (right to buy) 2026-02-12 A A 595,000 $0.00 595,000 D $1.71 · — to 2036-02-12 595,000 Common Stock (F3) 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.